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Methods

Study design and population
In this retrospective study, 41 patients (166 vertebrae) with MM who underwent PV between November 2008 and May 2014 were included. The only indication for PV was severe back pain. Severe pain generally limited body movements of patients and did not respond to different analgesics. Most of our patients were using level 3 (moderate to severe pain) analgesics (opiate analgesics). There was no neurologic deficit in any of the patients. Magnetic resonance imaging (MRI) was performed before the procedure, in order to assess vertebral involvement of MM. Conventional sagittal T1-weighted, T2-weighted and short tau inversion recovery (STIR) images were acquired on a 3.0 T (Achieva TX, Philips Medical systems) or a 1.5 T scanner (Magnetom Vision plus, Siemens Medical systems) using a spine coil. Sagittal postcontrast T1-weighted images were acquired after administration of 0.1 mmol/kg contrast media (Dotarem®; Guerbet or Magnevist®, Bayer Healthcare) when necessary. Vertebral involvement was determined by clinical and radiologic assessments. Presence of back pain and radicular pain raised clinical suspicion for vertebral involvement. The degree of vertebral involvement in MM was assessed using the semiquantitative visual assessment index showing vertebral deformity developed by Genant et al. (9) . In this index, loss of height is evaluated as grade 0, normal; grade 1, 20%-25% mild; grade 2, 25%-40% moderate; grade 3, >40% severe. This study was approved by the local clinical research ethics committee.
Procedural technique
PV was performed in sterile conditions under analgosedation (midazolam 0.03 mg/kg intravenous [IV] and/or fentanyl 1 µ/kg IV and/or ketamine 1 mg/kg IV and/or propofol 3-5 mg/kg IV and/or pethidine 1 mg/kg intramuscular), in a biplane, flat-paneled angiography unit (AXIOM Artis FD Biplane Angiosuite, Siemens). Ampicillin 1000 mg/sulbactam 500 mg IV combination was administered for preprocedural antibioprophylaxis. Patients were laid on the angiography table in a prone position. During the procedure, a cement vertebroplasty system (OptiMed Medical Devices, Ettlingen) or kyphon vertebroplasty kit (Kyphon Inc.) involving 10-or 13-gauge single-use-only bone biopsy needles was used. Biopsy needles were placed with the help of anteroposterior and/or lateral fluoroscopic imaging and left transpedicular, right transpedicular, and bipedicular approaches were used. Polymethylmethacrylate (PMMA) (Cemento Fixx, Optimed) bone cement was prepared and applied to the vertebral body using biopsy needles in a slow and controlled way manually or using an injection gun. The cement was administered principally to the lytic zone of the vertebrae. A maximum number of four sessions was performed on a single patient. After the procedure, patients were held in the observation room for three hours and subsequently discharged within the same day.
Pain assessment
In order to assess the pain scores of MM patients with vertebral involvement, a visual analogue scale (VAS) was used. VAS scores of the patients were recorded one day before, one day after, one week after, and three months after PV. VAS involved the standard pain scale between 0 and 10 (0, no pain; 10, intolerable, the most severe pain ever felt in patient's life) in order to determine the level of pain objectively. Before and after VAS scores were assessed by talking to the patients face to face or contacting them by phone.
Statistical analysis
Statistical analysis of data was done using the SPSS 22.0 statistical package program. Descriptive statistics were determined in terms of average±standard deviation or median (minimum-maximum). Categorical data was determined as frequency and percentage. Wilcoxon signed rank test was used to compare dependent groups. Repeated VAS measurements of groups were compared by taking difference values between them into consideration. The level of significance was determined as α=0.05.
Results
Between November 2008 and May 2014, 24 men (58.5%) and 17 women (41.5%) with MM underwent PV. The average age of the patients was 60.63±11.24 (range, 39-84 years).
Main points
• Our study shows that median pain scores of multiple myeloma patients decreased significantly following percutaneous vertebroplasty (PV).
• PV decreases back pain due to vertebral involvement in multiple myeloma patients.
• PV is an effective and safe method for patients with multiple myeloma. .00
* PV was performed on 166 vertebrae, of which, 86 were thoracic (51.8%) and 80 were lumbar (48.2%). The PV procedure was performed at T4-L5 vertebral levels. PV was most frequently performed at the L1 level (n=22/166; 13.3%) for lumbar and at the T12 level (n=19/166; 11.5%) for thoracic vertebrae. According to the semiquantitative visual assessment index developed by Genant et al. (9) , loss of height was grade 0 in 12 vertebrae (7.2%), grade 1 in 47 vertebrae (28.3%), grade 2 in 50 vertebrae (30.1%), and grade 3 in 57 vertebrae (34.4%).
The PV procedure was performed in a single session on 27 patients. Two or more sessions were performed on 14 patients (nine patients had two sessions, four patients had three sessions, and one patient had four sessions).
The median number of PV-performed vertebrae per session was one (range, 1-4), and three vertebrae received PV (range, 1-11) per patient. The median duration per session was 43.5 minutes (range, 18-78). The median volume of PMMA injected into the vertebral body during PV was 6 mL (range, [3] [4] [5] [6] [7] [8] [9] [10] .
The effectiveness of PV was assessed using VAS pain scores before and after PV, the amount of PMMA applied to the vertebral body and PMMA leakages during the procedure.
Median VAS scores of patients decreased from 9 (range, 3-10) one day before the procedure, to 6 (range, 0-10) one day after the procedure, to 3 (range, 0-10) one week after the procedure, and eventually to 1 (range, 0-10) three months after the procedure (P < 0.001) (Fig. 1 ). There was a significant difference between the average VAS scores at one day before and one day after the procedure, one day before and at one week after the procedure and one day before and three months after the procedure (P < 0.001, for all).
No complications were observed in 98 vertebral levels (59%). There were PMMA leakages in a total of 68 vertebrae (41%); 25 vertebrae (15.1%) had leakages into the disc, 36 vertebrae (21.7%) into the epidural or paravertebral vein, and seven vertebrae (4.2%) into both the disc and the epidural or paravertebral vein. No neurologic deficit or clinical symptom was observed because of these leakages.
VAS scores measured at one day, one week, and three months after the procedure were significantly reduced compared with the preprocedure score in patients with and without complications (P < 0.001, P < 0.001, and P < 0.001 in the group with complications and P = 0.007, P = 0.007, and P = 0.007 in the group with no complications, respectively). No statistically significant difference was observed with regard to changes of VAS scores obtained before and after the procedure between the two groups (P = 0.086, P = 0.777, P = 0.127, and P = 0.051, for one day before, one day after, one week after, and three months after, respectively). There was no statistically significant relationship between the applied cement volume and the VAS score decrease after the procedure (P = 0.797, P = 0.257, P = 0.732, and P = 0.864, for one day before, one day after, one week after, and three months after, respectively). There was no statistically
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significant relationship between vertebral height loss and the decrease of VAS scores after the procedure (P = 0.394, P = 0.247, P = 0.052, and P = 0.113 for one day before, one day after, one week after, and three months after, respectively). 
Discussion
This study demonstrates that PV decreases back pain due to vertebral involvement and that it is an effective method for patients with MM. One of the main reasons for morbidity in MM is skeletal system involvement. MM usually affects the spinal column and causes vertebral collapse and acute pain (10) . Patients need to be bedridden for weeks, use high doses of opioid analgesics and rarely receive palliative radiotherapy. Vertebral fractures can increase morbidity and mortality by causing spinal deformity, resistant pain, and spinal cord compression. The main aim of treating vertebral fractures due to MM should be to reduce pain and to provide functional restoration (11) . Most of our patients had been using level 3 (moderate to severe pain) analgesics (opiate analgesics) and all patients had pain unresponsive to these analgesics in the preprocedural period. The need for analgesics decreased after the procedure.
PV is a minimally invasive procedure where PMMA bone cement is injected into the vertebral body. Strengthening vertebra with PV helps support the vertebral structure in vertebral fractures which may relieve, pain due to fractures (12). Chen et al. (11) performed PV on 36 vertebrae of 24 patients who had vertebral fractures secondary to MM. They showed that the mean VAS score before the procedure was 9 and it decreased to 3.8 one day after, to 3.5 three months after, and to 4.7 one year after the procedure. Anselmetti et al. (13) reported that the median score of 106 patients with vertebral fractures due to MM decreased from 9 (4-10) to 1 (0-9) after PV. In a study of 64 myeloma-associated vertebral levels, Simony et al. (14) observed the VAS score decrease from 7.6 in the preoperative period to 3.2 three months after PV. In our study, a significant decrease was present in median VAS scores of 41 patients (166 vertebrae) before PV compared with the scores after PV. This significant decrease in VAS scores after the procedure is in accordance with the limited amount of literature data on the subject (11, 13, 14) . PV provides effective and fast relief for patients with vertebral pain due to MM.
The effectiveness of PV can be related to many factors. The most important one of which being the biomechanical mechanism (11) . PMMA used during PV helps with stabilizing microfractures and strengthening the treated vertebra (15, 16) . PMMA can cause damage in nerve endings and pain receptors because of the heat released during polymerization. Coagulation of tumoral tissue can also be directly induced. In addition, direct cytotoxic effects can cause tumor necrosis. For these reasons, a small amount of cement can induce a significant reduction in pain (17) . Yang et al. (2) used 3-9.5 mL of cement in PV procedures for MM. In our study, the PMMA amount used to reach adequate vertebral stiffness ranged 3-10 mL.
During the PV procedure, low viscosity cement needs to be applied to collapsed vertebra in a quick and effective way and with high pressure. In this case, there is a risk of cement leakage outside the vertebra (18) . Neural compression, radiculopathy, and pulmonary embolism can be observed due to cement leakage outside the vertebra. Cement leakage into the disc or paravertebral area can also be observed. These (19) . La Maida et al. (10) reported a cement leakage rate of 27.7% during PV on 18 vertebral fracture levels due to MM. Anselmetti et al. (13) reported a cement leakage rate of 22.9% on vertebral fractures due to MM after PV procedure on 106 patients. In our study, cement leakage was observed in 68 of 166 vertebral levels (41%) during the PV procedure. This high rate of cement leakage can be due to high pressure application of the low viscosity cement into the vertebra. VAS scores within one day, one week, and three months after the procedure were significantly reduced compared with the score one day before the procedure in both groups with and without complications. No statistically significant difference was observed with
Percutaneous vertebroplasty for vertebral pain in multiple myeloma a b regard to changes of VAS scores obtained before and after (within one day, one week, and three months) the procedure between the two groups. Khan et al. (8) determined no relationship between VAS score decrease and the presence of cement leakage in their systemic literature review, and this was compatible with our results. Our study has some limitations. It is a retrospective study without a control group, follow-up with most patients is inadequate because of their primary malignancies, and some patients were reached only by phone, although face to face communication would have been more effective. Another limitation is the assessment of VAS scores at a maximum of three months after the procedure. The reasons for this short interval were difficulties in reaching some patients by phone and in assessing them on control examination.
In conclusion, PV is a simple, effective, reliable, easy to perform and minimally invasive procedure. For this reason, we believe that PV should be preferred to treat acute back pain due to vertebral fractures and to stabilize the vertebra in patients with MM. Treatment of vertebral fractures can be performed effectively and safely with PV.
